I 
115TH CONGRESS 
2D SESSION 
H. R. 5580 
To authorize the Secretary of Health and Human Services to conduct pro-
grams to address the usage of illicit drugs, particularly fentanyl, and 
for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 23, 2018 
Ms. KUSTER of New Hampshire (for herself, Mr. MACARTHUR, Mr. JENKINS 
of West Virginia, and Mr. NORCROSS) introduced the following bill; which 
was referred to the Committee on Energy and Commerce 
A BILL 
To authorize the Secretary of Health and Human Services 
to conduct programs to address the usage of illicit drugs, 
particularly fentanyl, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Surveillance and Test-
ing of Opioids to Prevent Fentanyl Deaths Act of 2018’’ 
or the ‘‘STOP Fentanyl Deaths Act of 2018’’. 
VerDate Sep 11 2014 
22:45 Apr 25, 2018
Jkt 079200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H5580.IH
H5580
daltland on DSKBBV9HB2PROD with BILLS
SEC. 2. PUBLIC HEALTH LABORATORIES TO DETECT 
FENTANYL. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services (in this section referred to as the ‘‘Sec-
retary’’) shall establish a program to award grants to Fed-
eral, State, and local agencies for the establishment or op-
eration of public health laboratories to detect fentanyl, its 
analogues, and other synthetic opioids, as described in 
subsection (b). 
(b) STANDARDS.—The Secretary, acting through the 
Assistant Secretary for Mental Health and Substance Use, 
and in consultation with the Director of the National In-
stitute of Standards and Technology, shall— 
(1) develop standards for effectively handling 
and testing fentanyl, its analogues, and other syn-
thetic opioids; and 
(2) include in such standards procedures for en-
countering new and emerging synthetic opioid for-
mulations and reporting those findings to other Fed-
eral, State, and local public health laboratories. 
(c) LABORATORIES.—Each public health laboratory 
funded under subsection (a) shall— 
(1) agree to follow the standards established 
under subsection (b) and be capable of providing 
systematic and routine laboratory testing of drugs 
for the purposes of obtaining and disseminating pub-
VerDate Sep 11 2014 
22:45 Apr 25, 2018
Jkt 079200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H5580.IH
H5580
daltland on DSKBBV9HB2PROD with BILLS
lic health information to Federal, State, and local 
public health officials, laboratories, and other enti-
ties the Secretary deems appropriate; 
(2) work with law enforcement agencies and 
public health authorities to develop real-time infor-
mation on the purity and movement of fentanyl, its 
analogues, and other synthetic opioids; 
(3) assist State and local law enforcement agen-
cies in testing seized drugs when State and local fo-
rensic laboratories request additional assistance; and 
(4) provide early warning information and ad-
vice to Federal, State, and local law enforcement 
agencies and public health authorities of potential 
significant changes in the supply of fentanyl, its 
analogues, and other synthetic opioids. 
(d) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$15,000,000 for each of fiscal years 2018 through 2022. 
SEC. 3. ENHANCED FENTANYL SURVEILLANCE. 
(a) IN GENERAL.—The Director of the Centers for 
Disease Control and Prevention shall enhance its drug 
surveillance program by— 
(1) expanding its surveillance program to in-
clude all 50 States and the territories of the United 
States; 
VerDate Sep 11 2014 
22:45 Apr 25, 2018
Jkt 079200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H5580.IH
H5580
daltland on DSKBBV9HB2PROD with BILLS
(2) increasing and accelerating the collection of 
data on fentanyl, its analogues, and other synthetic 
opioids, including related overdose data from medical 
examiners and drug treatment admissions; and 
(3) utilizing available and emerging information 
on fentanyl, its analogues, and other synthetic 
opioids, including— 
(A) the National Drug Early Warning Sys-
tem; 
(B) State and local public health authori-
ties; and 
(C) Federal, State, and local public health 
laboratories. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$10,000,000 for each of fiscal years 2018 through 2022. 
SEC. 4. PILOT PROGRAM FOR POINT-OF-USE TESTING OF 
ILLICIT DRUGS FOR DANGEROUS CONTAMI-
NANTS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Assistant Secretary 
for Mental Health and Substance Use, in coordination 
with the Director of the Centers for Disease Control and 
Prevention, shall— 
VerDate Sep 11 2014 
22:45 Apr 25, 2018
Jkt 079200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H5580.IH
H5580
daltland on DSKBBV9HB2PROD with BILLS
(1) establish a pilot program through which 5 
State or local agencies conduct, in 5 States, point- 
of-use testing of illicit drugs for dangerous contami-
nants; 
(2) establish metrics to evaluate the success of 
the pilot program in reducing drug overdose rates; 
and 
(3) based on such metrics, conduct an annual 
evaluation of the pilot program and submit an an-
nual report to the Congress containing the results of 
such evaluation. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this section, there is authorized to be appropriated 
$5,000,000 for each of fiscal years 2018 through 2022. 
Æ 
VerDate Sep 11 2014 
22:45 Apr 25, 2018
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\H5580.IH
H5580
daltland on DSKBBV9HB2PROD with BILLS